Peptide News Digest

Section 232 Tariffs Live + $500B Onshoring, 503B GLP-1 Docket Closes, Q2 Big-Three Preview, Compounded Tirzepatide-B12 Study

Section 232 100% pharma tariffs kick in for 17 firms; $500B+ US onshoring pledged. 503B GLP-1 docket closes. Q2 Merck/Lilly/Novo preview next week.

4 stories · Covering regulatory, industry, research

Editor's Note

Saturday opens the weekend after the most substantive US pharmaceutical policy day since the July 23-24 PCAC vote. The Section 232 pharmaceutical tariff structure took effect Friday July 31, 2026 for the 17 companies named in Annex III of the Executive Order, with 100% duties on patented drug and API imports absent an onshoring agreement (which reduces the tariff to 20%). Industry response ahead of the deadline: over $500 billion in announced US pharmaceutical manufacturing investment commitments per Trump administration reporting, with independent analyst tallies of $370-480 billion in announced US pharma manufacturing investment for the 2025-2030 period. The broader pharmaceutical industry faces a September 29 deadline for additional tariff applicability. Generic pharmaceuticals, biosimilars, and their ingredients are expressly excluded from Section 232 at this time. Separately, the FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30 after a Federal Register extension from the original June 29 deadline. Q2 2026 earnings from the peptide-and-obesity big three arrive next week: Merck (Tuesday August 4), Eli Lilly (Wednesday August 5, with Foundayo weekly prescriptions near 20,000 as the analyst focus number), and Novo Nordisk (Wednesday August 5 H1 2026 results). A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond and form a new molecule not present in the FDA-approved drug, adding to the pharmacovigilance case against compounded GLP-1 formulations.

Regulatory

Section 232 Pharmaceutical Tariff Structure Took Effect Friday July 31, 2026 for the 17 Companies Named in Annex III of the Trump Administration Executive Order With 100% Duties on Patented Drug and Active Pharmaceutical Ingredient (API) Imports Absent an Onshoring Agreement (Which Reduces the Tariff to 20%); Broader Pharmaceutical Industry Faces September 29, 2026 Deadline for Additional Tariff Applicability; Generic Pharmaceuticals, Biosimilars, and Their Ingredients Are Expressly Excluded; Industry Response Ahead of the Deadline Includes Over $500 Billion in Announced US Pharmaceutical Manufacturing Investment Commitments Per Trump Administration Reporting With Independent Analyst Tallies of $370-480 Billion for the 2025-2030 Period

The Section 232 pharmaceutical tariff structure took effect Friday July 31, 2026 for the 17 companies named in Annex III of the Trump administration Executive Order. Tariff structure: 100% duties on patented drug and active pharmaceutical ingredient (API) imports absent an onshoring agreement; companies that negotiated an onshoring agreement before the July 31 deadline receive a reduced 20% tariff. The broader pharmaceutical industry faces a September 29, 2026 deadline for additional tariff applicability at the higher rates. Generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 at this time (President Trump separately announced Tuesday July 21 that imported generics would face zero tariffs for two years starting August 2028). Industry response ahead of the July 31 deadline: over $500 billion in announced US pharmaceutical manufacturing investment commitments per Trump administration reporting. Independent analyst tallies documented $370-480 billion in announced US pharma manufacturing investment for the 2025-2030 period. Companies affected include Novo Nordisk, Eli Lilly, Merck, AstraZeneca, Sanofi, AbbVie, Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen. Drawback relief provisions apply for API and finished-drug exports made from imported components. The tariff structure was formally imposed via the Executive Order 120 days before the July 31 effective date.

#section-232 #pharmaceutical-tariffs #trump-administration #onshoring-agreement #manufacturing-investment #annex-iii #generic-exclusion #biosimilar-exclusion #api-tariffs #drawback-relief
Regulatory

FDA Public Comment Period on the April 30, 2026 Proposed Rule to Permanently Exclude Semaglutide, Tirzepatide, and Liraglutide From the Section 503B Bulks List Closed Thursday July 30, 2026 After a Federal Register-Extended Deadline From the Original June 29 Cutoff; The FDA Found No Clinical Need for Outsourcing Facilities to Compound the Three GLP-1 Molecules From Bulk Drug Substances; Finalization of the Rule Would Close the Last Legal Pathway for Large-Scale FDA-Registered 503B Outsourcing Facility Compounding of the Branded GLP-1s, Following the December 2024 Semaglutide Shortage Resolution and February 2025 Tirzepatide Shortage Resolution

The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.

#fda #503b-bulks-list #semaglutide #tirzepatide #liraglutide #comment-period-close #outsourcing-facility #clinical-need #peptide-compounding #faers
Industry

Q2 2026 Earnings Preview for the Peptide-and-Obesity Big Three Next Week: Merck (NYSE: MRK) Reports Tuesday August 4 With Analyst Consensus at $1.36 Diluted EPS Down 36.2% YoY From $2.13 (Reflecting Post-Keytruda Loss-of-Exclusivity Repositioning and LIPFENDRA/Enlicitide Launch Costs), Eli Lilly (NYSE: LLY) Reports Wednesday August 5 With Analyst Consensus at $20.26 Billion Revenue and $6.71 EPS (Prediction Markets Show 70% Probability of Another Earnings Beat, 96.4% Odds Mounjaro Clears $7.5 Billion Q2, 87% Odds Zepbound Tops $4 Billion Q2, and Foundayo Weekly Prescriptions Near 20,000 as the Analyst Focus Number), and Novo Nordisk Reports Wednesday August 5 H1 2026 Results

Q2 2026 earnings from the peptide-and-obesity big three arrive next week. Merck (NYSE: MRK) reports Tuesday August 4 before market open with analyst consensus at $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025), reflecting post-Keytruda loss-of-exclusivity strategic repositioning and LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor approved July 16, 2026) launch costs. Eli Lilly (NYSE: LLY) reports Wednesday August 5 before market open with analyst consensus at $20.26 billion revenue and $6.71 EPS. Prediction markets put a 70% probability on another Lilly earnings beat, 96.4% odds Mounjaro (tirzepatide) clears $7.5 billion Q2, 87% odds Zepbound (tirzepatide) tops $4 billion Q2, and Foundayo (orforglipron, oral small-molecule GLP-1) weekly prescriptions near 20,000 as the primary analyst focus number after the April 2026 FDA approval. Novo Nordisk reports Wednesday August 5 H1 2026 results (Novo reports half-year rather than quarterly), with Wegovy pill (oral semaglutide 25/50 mg) Q1 2026 sales of approximately $354 million providing the H1 baseline. The three earnings prints together will frame second-half 2026 obesity market trajectory and the competitive positioning across incretin, macrocyclic peptide, and small-molecule oral GLP-1 franchises.

#merck #eli-lilly #novo-nordisk #q2-2026-earnings #lipfendra #mounjaro #zepbound #foundayo #wegovy #prescription-volume #earnings-preview
Research

2026 Chemistry Study Documented That When Tirzepatide (Mounjaro, Zepbound) Is Compounded With Vitamin B12 the Two Substances Can Chemically Bond and Form a New Molecule Not Present in the FDA-Approved Drug Product, Adding to the Pharmacovigilance Case Against Compounded GLP-1 Formulations Amid the July 30 FDA 503B Bulks List Exclusion Comment Period Close and the Documented 990 Adverse Events for Compounded Semaglutide and 730+ for Compounded Tirzepatide in the FDA Adverse Event Reporting System (FAERS)

A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.

#compounded-glp-1 #tirzepatide #vitamin-b12 #chemistry #novel-molecule #compounding-additives #pharmacovigilance #faers #503b-bulks-list #safety